Processing, Please wait...

  • Publisher Home
  • Home
  • 🔙 Back
  • 📚 Journals
    • ⚙️ IJIEC - Industrial Engineering Computations
    • 🌐 IJDNS - Data and Network Science
    • 🧪 CCL - Current Chemistry Letters
    • 💹 AC - Accounting
    • 🎯 DSL - Decision Science Letters
    • 🚛 USCM - Uncertain Supply Chain Management
    • 🏗️ JPM - Journal of Project Management
    • 🏥 HE - Healthcare Engineering
    • 📈 SCI - Scientometrica
    • 🔩 ESM - Engineering Solid Mechanics
    • 🌿 JFS - Journal of Future Sustainability
    • 💼 MSL - Management Science Letters
  • 📝 Submit Article
  • 📊 Statistics
  • 📋 About
    • 📄 About Us
    • 📰 Blog
    • 📢 News
    • 📧 Contact
  • 📺 Tutorial
  • Search:
  • Advanced Search

Growing Science » Tags cloud » Neuroprotection

⭐ Highly Cited Articles

  • Jaya Algorithm
  • Rao Algorithm
  • TLBO Algorithm
  • ChatGPT and Blended Learning

Journals

  • IJIEC (840)
  • IJDS (1032)
  • DSL (759)
  • ESM (434)
  • CCL (563)
  • JPM (350)
  • AC (572)
  • JFS (106)
  • MSL (2658)
  • USCM (1104)
  • HE (56)
  • SCI (53)

🔑 Keywords

Jordan(175)
Supply chain management(172)
Vietnam(154)
Customer satisfaction(124)
Performance(117)
Supply chain(115)
Artificial intelligence(108)
Service quality(101)
Competitive advantage(100)
SMEs(95)
Tehran Stock Exchange(94)
Sustainability(94)
optimization(88)
Financial performance(86)
TOPSIS(85)
Trust(85)
Organizational performance(81)
Job satisfaction(81)
Genetic Algorithm(81)
Social media(80)


» Show all keywords

✍️ Authors

Naser Azad(82)
Zeplin Jiwa Husada Tarigan(70)
Mohammad Reza Iravani(65)
Endri Endri(45)
Hotlan Siagian(43)
Muhammad Alshurideh(42)
Dmaithan Almajali(39)
Jumadil Saputra(37)
Muhammad Turki Alshurideh(35)
Ahmad Makui(33)
Sautma Ronni Basana(33)
Barween Al Kurdi(32)
Basrowi Basrowi(31)
Mohammad Khodaei Valahzaghard(30)
Haitham M. Alzoubi(30)
Ni Nyoman Kerti Yasa(30)
Hassan Ghodrati(30)
Shankar Chakraborty(29)
Sulieman Ibraheem Shelash Al-Hawary(28)
Mahmoud Allahham(28)


» Show all authors

🌍 Countries

1. Algeria (52)
2. Angola (2)
3. Argentina (22)
4. Armenia (2)
5. Australia (52)
6. Austria (2)
7. Bahrain (26)
8. Bangladesh (58)
9. Belarus (4)
10. Belgium (3)
11. Benin (2)
12. Benin Republic (1)
13. Bhutan (1)
14. Bosnia and Herzegovina (1)
15. Botswana (9)
16. Brazil (40)
17. Brunei (1)
18. Bulgaria (1)
19. Burkina Faso (1)
20. Cameroon (1)
Total: 121 countries

Show all countries
Sort articles by: 📖 Volume | 📅 Date | ⭐ Most Rates | 👁️ Most Views | 🚀 Rising Stars | 🔗 Citations (Scopus) | 🔥 Hot Papers
1.

A Scientometrics survey of GLP-1 receptor agonists in neurodegenerative disorders: An evolving paradigm from metabolic to brain health Pages 125-134 PDF Download PDF

Authors: Nastaran Makoui

doi 10.5267/j.sci.2025.4.004

🔑 Keywords: GLP-1 receptor agonist, Neurodegeneration, Alzheimer's disease, Parkinson's disease, Obesity, Type 2 diabetes, Scientometrics, Neuroprotection, Semaglutide, Liraglutide

Abstract:
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally designed for the management of type 2 diabetes (T2DM) and weight loss, have turned out to be a potential therapeutic target for neurodegenerative diseases. The present scientometrics study carries out a detailed analysis of 119 scienctific studies to the front of publications in the Scopus database (2011-2026) and maps the academic structure, thematic development, and main research areas in this rapidly growing field. The examination points out a strong increase in the number of publications, particularly from 2022 onward, which marks a major paradigm shift in considering GLP-1 RAs as possible neuroprotectors. Among the main research areas are: (1) Mechanistic Preclinical Studies, which account for the majority of publications and explain insulin signaling, neuroinflammation, oxidative stress, apoptosis and synaptic plasticity through the different pathways; (2) Clinical and Real-World Evidence, comprising of retrospective cohort studies and the first randomized controlled trials (RCTs) that show a decrease in dementia and Parkinson's disease (PD) among T2DM patients; (3) Drug-Specific Investigations, that discuss the effects of liraglutide, semaglutide, exendin-4, and the dual agonist tirzepatide; and (4) Disease-Specific Applications, primarily concentrating on Alzheimer's disease (AD) and PD. The field is characterized by a powerful shift from animal models to human trials and is starting to test applications in other areas besides the classic neurodegeneration such as cognitive dysfunction in obesity, psychiatric disorders and other CNS conditions. This survey encapsulates the present knowledge, puts the limelight on the contributions of pivotal Ais and research groups, and points out the future directions for this very promising area of therapeutic development.
Details
  • 0
  • 1
  • 2
  • 3
  • 4
  • 5

Journal: SCI | Year: 2025 | Volume: 1 | Issue: 3 | Views: 650

 

® 2010-2026 GrowingScience.Com